Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Boston Scientific (NYSE:BSX) and the rest of the medical devices & supplies - diversified stocks fared in Q4.
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Date: February 24, 2026 By: Financial Research Analyst Introduction For years, Medtronic plc (NYSE: MDT) was viewed by Wall Street as a reliable but sluggish giant—a "Dividend Aristocrat" that offered safety but lacked the high-octane growth of its specialized med-tech peers. That narrative is shifting rapidly. Today, February 24, 2026, marks a watershed moment for [...]
In a definitive sign that the medical technology sector has moved past its post-pandemic stagnation, Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for the third fiscal quarter of 2026. On February 17, 2026, the Dublin-based medical device giant announced total revenue of $9.017 billion,
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for an enterprise value of approximately $14.5 billion. This transaction, structured as a mix of 73% cash
Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for its fiscal third quarter of 2026, marking a significant turning point for the medical technology giant. The results, released on February 17, 2026, surpassed analyst expectations and highlighted a robust recovery in elective procedure volumes and a
Today’s Date: February 17, 2026 Introduction Medtronic plc (NYSE: MDT) has long been the sleeping giant of the medical technology sector. For years, the Dublin-domiciled powerhouse was viewed by Wall Street as a stable but slow-moving conglomerate, hampered by its own scale and a fragmented organizational structure. However, the narrative has shifted dramatically in early [...]
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors.
A select few continue to innovate and expand, setting themselves up for long-term success.
Boston Scientific’s fourth quarter results were met with a significant negative market reaction, despite meeting revenue expectations and delivering adjusted earnings above analyst consensus. Management pointed to broad-based growth, with electrophysiology (EP), WATCHMAN, interventional oncology, and neuromodulation cited as standouts. However, concerns emerged around sequential stagnation in U.S. EP sales and a modest miss in U.S. WATCHMAN, both key franchises for Boston Scientific’s ongoing momentum. CEO Michael Mahoney acknowledged these issues, stating, “We anticipated some share loss in EP given competitive launches, but we remain confident in our above-market growth expectations.”
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company’s possible violations of the federal securities laws.
Today, February 9, 2026, marks a watershed moment for Becton, Dickinson and Company (NYSE: BDX). The medical technology giant, commonly known as BD, has officially closed its transformative $17.5 billion combination with Waters Corporation (NYSE: WAT), effectively spinning off its Biosciences and Diagnostic Solutions units to create a more streamlined "New BD." Simultaneously, the company [...]
Stocks with low volatility can be a great foundation for a portfolio, especially for investors looking to reduce risk.
While they don’t often make headlines, these companies provide consistency in an unpredictable market.
Law Offices of Howard G. Smith announces an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
As of February 6, 2026, the global financial landscape is being reshaped by an unprecedented "wall of capital." After nearly two years of stagnation caused by valuation gaps and high borrowing costs, the private equity industry has entered a transformative period of deployment. With a record-shattering $3.2 trillion in
The long-awaited "deal drought" has officially broken. As of early February 2026, the American financial landscape is being reshaped by a massive resurgence in corporate deal-making, punctuated by a staggering 111.5% year-over-year increase in transactions valued over $100 million at the close of 2025. This tidal wave of capital
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal represents the largest acquisition for Boston Scientific in over two decades, signaling a transformative
A group of emerging biotech and healthcare companies is gaining attention as they advance novel technologies across oncology, regenerative medicine, infection prevention, and precision radiotherapy—sectors that remain top priorities for global healthcare systems and investors alike. From late-stage cancer immunotherapy programs to next-generation hygiene platforms and regenerative biologics, these five companies represent distinct but complementary approaches to addressing high-value medical needs.
The "Great Hesitation" in global finance has officially come to an end. In the opening weeks of 2026, the private equity landscape has undergone a dramatic transformation, shifting from two years of defensive posturing to a full-scale dealmaking renaissance. Driven by a record-shattering $2 trillion in "dry powder" and a
February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left investors and analysts debating the future of high-growth medtech. For over a decade, Boston Scientific has been the gold standard for consistent execution and category [...]
Medical device company Boston Scientific (NYSE:BSX) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 15.9% year on year to $5.29 billion. The company expects next quarter’s revenue to be around $5.19 billion, close to analysts’ estimates. Its non-GAAP profit of $0.80 per share was 2.4% above analysts’ consensus estimates.
